Ramucirumab: first global approval (Q38219239)

31 August 2017

title

Ramucirumab: first global approval (English)

1 reference

31 August 2017

Raewyn M Poole

1

1 reference

31 August 2017

Asha Vaidya

series ordinal

2

1 reference

31 August 2017

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1047-1058

1 reference

The progress of targeted therapy in advanced gastric cancer

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

VEGFA and tumour angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

The structural basis for the function of two anti-VEGF receptor 2 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0244-2

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

21 January 2018

1 reference

12 December 2020

Prognostic value of vascular endothelial growth factor expression in gastric carcinoma

1 reference

12 December 2020

Metastatic gastric cancer - focus on targeted therapies

1 reference

12 December 2020

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.

1 reference

12 December 2020

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

12 December 2020

10.1007/S40265-014-0244-2

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1035014957

0 references

1 reference